Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature. 2013;545:423–31.

Article  Google Scholar 

Mailankody S, Devlin SM, Landa J, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387(13):1196–206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–8.

Article  CAS  PubMed  Google Scholar 

Pedersen MG, Møller BK, Bak RO. Recent advances in the development of anti-FLT3 CAR T-cell therapies for treatment of AML. Biomedicines. 2022;10(10):2441.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, Böltz S, Manger B, Mackensen A, Schett G. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567–9.

Article  PubMed  Google Scholar 

Lin X, Lee S, Sharma P, et al. Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-cell biologics license application approvals from a statistical perspective. J Clin Oncol. 2022;40(30):3501–9.

Article  CAS  PubMed  Google Scholar 

Exley AR, Rantell K, McBlane J. Clinical development of cell therapies for cancer: the regulators’ perspective. Eur J Cancer. 2020;138:41–53.

Article  PubMed  Google Scholar 

Duncan BB, Dunbar CE, Ishii K. Applying a clinical lens to animal models of CAR-T cell therapies. Mol Ther Methods Clin Dev. 2022;27:17–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52.

Article  PubMed  Google Scholar 

Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16.

Article  CAS  PubMed  Google Scholar 

Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.

Article  CAS  PubMed  Google Scholar 

Siddiqi T, Abramson J, Li D, et al. Patient characteristics and pre-infusion biomarkers of inflammation correlate with clinical outcomes after treatment with the defined composition, CD19-targeted CAR T cell product, JCAR017 (lisocabtagene maraleucel; liso-cel). Presentation at the 59th American Society of Hematology Annual Meeting, Atlanta, GA, 9–12 December 2017.

Rotte A, Frigault MJ, Ansari A, et al. Dose-response correlation for CAR-T cells: a systematic review of clinical studies. J Immunother Cancer. 2022;10(12): e005678.

Article  PubMed  PubMed Central  Google Scholar 

U.S. Food and Drug Administration. Considerations for the design of early-phase clinical trials of cellular and gene therapy products. 2015.

Lin R, Zhou Y, Yan F, et al. BOIN12: bayesian optimal interval phase I/II trial design for utility-based dose finding in immunotherapy and targeted therapies. JCO Precis Oncol. 2020;4:PO.20.00257.

Li D, Whitmore JB, Guo W, et al. Toxicity and efficacy probability interval design for phase I adoptive cell therapy dose-finding clinical trials. Clin Cancer Res. 2017;23(1):13–20.

Article  CAS  PubMed  Google Scholar 

Zhou Y, Lin R, Lee JJ, et al. TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med. 2022;41(11):1918–31.

Article  PubMed  PubMed Central  Google Scholar 

Yuan Y, Hess KR, Hilsenbeck SG, et al. Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. Clin Cancer Res. 2016;22(17):4291–301.

Article  PubMed  PubMed Central  Google Scholar 

Delvin SM, Iasonos A, O’Quigley J. Phase I clinical trials in adaptive T-cell therapies. J R Stat Soc Ser C. 2021;2021(20):815–34.

Google Scholar 

Statistical Principles for Clinical Trials: Addendum: estimands and sensitivity analysis in clinical trials. 2019. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf

Statistical Considerations in CAR-T Cell Therapy Development. Presentation at the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop, 22–25 September 2020.

Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22(11):1530–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331–44.

Article  CAS  PubMed  Google Scholar 

Panhuber A, Titieni-Schuhmann A, Goetz G, et al.: CAR-T cell therapy: contrasting the evidence from pivotal trials with the real world evidence (RWE). 2022; HTA-Projektbericht 146

Gye A, Goodall S, De Abreu LR. A systematic review of health technology assessments of chimeric antigen receptor T-cell therapies in young compared with older patients. Value Health. 2022;25(1):47–58.

Article  PubMed  Google Scholar 

Hampson L, Chu J, Zia A, et al. Combining the target trial and estimand frameworks to define the causal estimand: an application using real-world data to contextualize a single-arm trial. Statistics in Biopharmaceutical Research. 2023. https://doi.org/10.1080/19466315.2023.2190931.

Article  Google Scholar 

Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019;111(7):646–54.

Article  PubMed  Google Scholar 

Chakraborty R, Hill BT, Majeed A, Majhail NS. Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies. Transpl Cell Ther. 2021;27(3):222–9.

Article  CAS  Google Scholar 

Xi J, Liu Y, Ping F, Fang L. Handling CRS/NT data in CAR-T studies and submission. Paper presented at PharmaSUG Conference, San Francisco, CA, 14–17 May 2023.

Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Bio Blood Marrow Transpl. 2019;25(4):625–38.

Article  CAS  Google Scholar 

Breyanzi FDA Approval Supporting Documents Clinical Review Memo. https://www.fda.gov/media/159602/download?attachment

Yescarta FDA Approval Supporting Documents Clinical Review and Evaluation. https://www.fda.gov/media/157687/download?attachment

Benefit-risk methodology project: Work package 2 report. EMA/549682/2010.

Hughes D, Waddingham E, Mt-Isa S, et al. Recommendations for benefit–risk assessment methodologies and visual representations. Pharmacoepidemiol Drug Saf. 2016;25(3):251–62.

Article  PubMed  Google Scholar 

Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

U.S. Food and Drug Administration. Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial. 2022

U.S. Food and Drug Administration. Long term follow-up after administration of human gene therapy products. 2020

U.S. Food and Drug Administration. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics guidance for industry. 2022

U.S. Food and Drug Administration. Decentralized clinical trials for drugs, biological products, and devices. 2023

Long KB, Young RM, Boesteanu AC, et al. CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success. Front Immunol. 2018;3(9):2740.

Article  Google Scholar 

Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease—a case series with follow-up. N Engl J Med. 2024;390(8):687–700.

Article  PubMed  Google Scholar 

Ananthakrishnan R, Green S, Previtali A, et al. Critical review of oncology clinical trial design under non-proportional hazards. Crit Rev Oncol Hematol. 2021;162: 103350.

Article  PubMed  Google Scholar 

U.S. Food and Drug Administration. Considerations for the development of chimeric antigen receptor (CAR) T cell products. 2022

Broussais F, Bay JO, Boissel N, et al. DESCAR-T, le registre national des patients traités par CAR-T Cells [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France]. Bull Cancer. 2021;108(10S):S143–54.

Article  PubMed  Google Scholar 

Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

U.S. Food and Drug Administration. 2022 Kymriah prescribing information

U.S. Food and Drug Administration. 2022 Yescarta prescribing information

U.S. Food and Drug Administration. 2022 Tecartus prescribing information

U.S. Food and Drug Administration. 2022 Breyanzi prescribing information

U.S. Food and Drug Administration. 2021 Abecma prescribing information

U.S. Food and Drug Administration. 2022 Carvykti prescribing information

Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hess G, Dreyling M, Oberic L, et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br J Haematol. 2023;202(4):749–59.

Article  CAS  PubMed  Google Scholar 

Shah BD, Ghobadi A, Oluwole OO, et al. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol. 2022;15(1):170.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghione P, Palomba ML, Patel AR, et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 2022;140(8):851–60.

Article  CAS